Sagimet Biosciences Inc - Series A — Cash Flow (NASDAQ:SGMT) | MetaTrader

Open full chart

Financials

Overview 성명 Statistics

Quarterly Annual

Cash from operating activities -23.77 M-42.44 M-45.65 M -45.65 M Cash from investing activities 12.58 M-61.68 M4.56 M 4.56 M Cash from financing activities 86.17 M104.82 M275 K — Free cash flow -23.77 M-42.44 M-45.65 M -45.65 M

뉴스

시티즌, MASH 진전 관련 Sagimet Biosciences 투자의견 재확인

Citizens reiterates Sagimet Biosciences stock rating on MASH progress

오펜하이머, MASH 임상 진행에 사지메트 주식 등급 재확인

Oppenheimer reiterates Sagimet stock rating on MASH trial progress

사지메트, 여드름 치료제 3상 안전성 데이터 발표 후 주가 상승

Sagimet stock rises after positive Phase 3 safety data for acne drug

Ascletis reports positive long-term safety data for acne drug denifanstat

Sagimet: Positive Denifanstat Combination PK Data Could Lead To Untapped Market (SGMT)

Sagimet reports positive Phase 1 results for MASH combination therapy

Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)

Sagimet Biosciences executive chairman sells $290k in shares

Sagimet 바이오사이언스 목표 주가, Citizens, 35달러로 상향